IPSC Stock Analysis: Buy, Sell, or Hold?
IPSC - Century Therapeutics, Inc. Common Stock
$1.76
-0.08 (-4.35%)
▼
5d:
-25.42%
30d:
+76.99%
90d:
+193.33%
WAIT
LOW Confidence
Analysis Updated: Feb 4, 2026 12:00 AM ET
Earnings: Mar 18, 2026
Get Alerted When IPSC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: IPSC is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: IPSC is down 25.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: IPSC is currently trading at $1.76, which is considered fair relative to its 30-day fair value range of $1.24 to $2.34.
Technical Outlook: Technically, IPSC is in a strong uptrend. Immediate support is located at $1.69, while resistance sits at $2.71. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.50 (+90.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IPSC is in a strong uptrend. Immediate support is located at $1.69, while resistance sits at $2.71. Short-term momentum is weak, with the stock down 4.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.50 (+90.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$1.24 -
$2.34
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.3%)
- BULLISH: Trading 90.2% below Wall St target ($3.50)
- WARNING: Recommendation downgraded due to -25.4% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$1.24 -
$2.34
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$1.69
Resistance Level
$2.71
Current Trend
Strong Uptrend
Technical data as of
Feb 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.90
Wall Street Target
$3.50
(+90.2%)
Revenue Growth (YoY)
12667.7%
Profit Margin
-23.4%
Last updated: February 04, 2026 2:25 PM ET
Data refreshes hourly during market hours. Next update: 3:25 PM
Data refreshes hourly during market hours. Next update: 3:25 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IPSC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Brent Pfeiffenberger
SELL
488 shares
2025-09-08
Douglas Carr
SELL
263 shares
2025-09-08
Gregory Russotti
SELL
539 shares
2025-09-08
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 46 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 56 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 53 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
